FVIII at the crossroad of coagulation, bone and immune biology: emerging evidence biological activities beyond hemostasis - Archive ouverte HAL Access content directly
Journal Articles Drug Discovery Today Year : 2021

FVIII at the crossroad of coagulation, bone and immune biology: emerging evidence biological activities beyond hemostasis

(1, 2, 3) , (1, 2, 3) , (4, 2, 3) , (4) , (1, 2, 3) , (5) , (6, 1, 3)
1
2
3
4
5
6

Abstract

Hemophilia A is an X-linked hereditary disorder related to the deficiency of coagulation factor VIII (FVIII) leading to spontaneous bleeding episodes particularly into joints and muscles. FVIII deficiency has been associated with altered bone remodeling, dysregulated macrophage polarization, and inflammatory processes combined with neoformation of abnormal blood vessels. Treatment based on FVIII can lead to the development of inhibitors that render FVIII concentrate infusion ineffective. In this context, hemophilia has entered a new therapeutic era with the development of new drugs (e.g. Emicizumab) to restore the hemostatic balance by bypassing pathologic acquired antibodies. The present review aims to discuss the potential extrahemostatic functions of FVIII which may be crucial information for defining the future therapies in hemophilia.
Fichier principal
Vignette du fichier
Cade et al. Drug Discovery Today Rev1&TabsFigs.pdf (1.19 Mo) Télécharger le fichier
Vignette du fichier
Supplementary Figure 1 .pdf (166.34 Ko) Télécharger le fichier

Dates and versions

inserm-03298299 , version 1 (23-07-2021)

Identifiers

Cite

Marie Cadé, Javier Munoz-Garcia, Antoine Babuty, M. Marc Fouassier, Marie-Françoise Heymann, et al.. FVIII at the crossroad of coagulation, bone and immune biology: emerging evidence biological activities beyond hemostasis: Factor VIIIbeyond hemostasis. Drug Discovery Today, 2021, pp.S1359-6446(21)00321-4. ⟨10.1016/j.drudis.2021.07.015⟩. ⟨inserm-03298299⟩
56 View
117 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More